Colorectal cancer is cancer that begins in the colon or rectum. It is one of the most common gastrointestinal cancers and a major cause of cancer burden worldwide.
Research found variation in guideline-concordant colorectal cancer care across hospitals and systems, while a separate study highlighted the role of specialized cancer nurses in reducing distress and improving support.
Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
Incyte has started the phase 3 Dawn-03 trial of INCB161734 plus chemotherapy in first-line KRAS G12D-mutant pancreatic cancer. The move comes while the phase 1 study remains halted in four European countries after pneumonitis cases, including one grade 5 event.
TMEM87A was identified as a mediator of ferroptosis resistance through buffering Golgi pH. In murine tumor models, TMEM87A ablation suppressed tumor progression and potentiated PD1 blockade therapy.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Recent advances in genetic science are shifting colorectal cancer screening toward direct detection of DNA changes. In India, CRC is now the fourth most common cancer, with more than 64,000 new cases and over 38,000 deaths reported in 2022.
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604909 |
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy |
RECRUITING | PHASE2 |
| NCT07599501 |
Nutritional Supplementation to Improve Colorectal Cancer Surgery |
NOT_YET_RECRUITING | NA |
| NCT07597759 |
Phase IIT Trial of SNA009 |
COMPLETED | EARLY_PHASE1 |
| NCT07595276 |
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07594067 |
TCR1188-ABC Cells in KRAS-mutated Cancers |
NOT_YET_RECRUITING | PHASE1 |
| NCT07592338 |
Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer |
COMPLETED | |
| NCT07590856 |
A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33 |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07589517 |
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07589205 |
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07587619 |
Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
